PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search
BNF Chapter
BNF Paragraph
Please select a BNF Chapter.
Search Results : Overactive bladder (adults) (Imipramine hydrochloride - Overactive bladder (adults))
Records returned : 16 (on 05 Nov 2024 at 10:51:22). Return to search results for ' Overactive bladder (adults) '.
Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
04.07.03
07.04.02
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
07.04.02
Green
Formulations :
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Preferred
1st line unless contra-indicated
Green (see narrative)
Formulations :
- Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Important
Only for patients with swallowing difficulties.
Prescribe as solifenacin 1mg/ml oral SUSPENSION
07.04.02
Green (see narrative)
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Important
Solifenacin is 1st line.
Mirabegron for use when antimuscarinics are contraindicated, patients with CNS adverse effects or patients requiring a more potent treatment.
07.04.02
Green (see narrative)
Formulations :
- Immediate release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Alternative 1st line in patients where anticholinergic burden is a problem or on medicines that interact.
Green (see narrative)
Formulations :
- Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
2nd line in patients where anticholinergic burden is a problem or on medicines that interact.
07.04.02
Green (see narrative)
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Important
3rd line - for patients requiring more potent treatment
07.04.02
Green (see narrative)
Formulations :
- Immediate release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
1st line in patients with renal impairment
07.04.02
Green (see narrative)
Formulations :
- Patches
ASPH
RSFT
SASH
SABP
Primary Care
Important
Solifenacin 1mg/ml oral SUSPENSION is preferred for patients with swallowing difficulties.
Oxybutynin patches are reserved for patients where an oral formulation is not suitable
N/A
Formulations :
- Intravesical
ASPH
RSFT
SASH
SABP
Primary Care
07.04.02
Non Formulary
Formulations :
- Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Important
Prescribe as solifenacin 1mg/ml oral SUSPENSION
07.04.02
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Important
Switch to solifenacin recommended (if appropriate)
07.04.02
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
07.04.02
Non Formulary
Formulations :
- Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
07.04.02
Non Formulary
Formulations :
- Modified release tablets
- Oral solution
- Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Switch to solifenacin recommended (if appropriate).
07.04.02
Non Formulary
Formulations :
- Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Important
Switch to solifenacin (or formulary alternative) recommended
For information about the icons and status values within this site, please refer to the keys below.
Icon/Links Key
NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq form to be completed
NICE
Traffic Light Status Key
Red
Amber
Green
Black
Amber Star
Green (see narrative)
Non Formulary
See Below
N/A
Blue
Green - Black
See narrative
Do not initiate in new patients